Mutational Testing

Home/Mutational Testing

It’s Time: The Life Raft Group Biomarker Testing Campaign – MaKayla Evans Talks Testing

Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.

By |2021-02-17T09:27:51-05:00February 17th, 2021|Mutational Testing, News|

It’s Time: The Life Raft Group Biomarker Testing Campaign – Resources List

Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. Here is a Resource list for GIST and other cancers.

By |2021-02-09T08:17:24-05:00February 8th, 2021|Mutational Testing, News|

It’s Time: The Life Raft Group Biomarker Testing Campaign – LRG Patient Registry Video

Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.

By |2021-02-08T11:47:40-05:00February 8th, 2021|Mutational Testing, News|

It’s Time: The Life Raft Group Biomarker Testing Campaign

Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is [...]

By |2021-02-08T11:17:58-05:00January 26th, 2021|Mutational Testing, News|

Dr. Gina D’Amato, GIST Specialist, Talks Advances in Sarcoma

In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.

By |2020-05-01T11:40:35-04:00May 1st, 2020|Mutational Testing, News, Research|

Blueprint Medicines Presents Cost of Testing Poster

Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.

By |2020-04-30T14:50:52-04:00April 30th, 2020|Mutational Testing, News, Patient Support|

LRG Assisted in CAP Guidelines Modifications with a Diagnostic Algorithm

The LRG, in collaboration with the Pediatric & SDH-Deficient GIST Consortium and key opinion leaders among the GIST pathology community (with Dr. Brian Rubin taking the lead), played a significant role in changing CAP Guidelines. CAP Guidelines are protocols for pathologists to instruct them on the process of diagnosing a disease based on tumor tissue samples.

By |2019-08-29T10:18:35-04:00August 29th, 2019|Advocacy, Mutational Testing, News|
Go to Top